Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer
Article first published online: 22 FEB 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 19, pages 4660–4669, 1 October 2012
How to Cite
Baquero, M. T., Hanna, J. A., Neumeister, V., Cheng, H., Molinaro, A. M., Harris, L. N. and Rimm, D. L. (2012), Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer, 118: 4660–4669. doi: 10.1002/cncr.27453
- Issue published online: 19 SEP 2012
- Article first published online: 22 FEB 2012
- Manuscript Accepted: 6 DEC 2011
- Manuscript Received: 26 SEP 2011
- microtubule-associated protein;
- quantitative analysis;
Microtubule-associated proteins (MAPs) endogenously regulate microtubule stability. Here, the prognostic value of stathmin, a destabilizing protein, was assessed in combination with MAP-tau, a stabilizing protein, in order to evaluate microtubule stabilization as a potential biomarker.
Stathmin and MAP-tau expression levels were measured in a breast cancer cohort (n = 651) using the tissue microarray format and quantitative immunofluorescence (AQUA) technology, then correlated with clinical and pathological characteristics and disease-free survival.
Univariate Cox proportional hazard models indicated that high stathmin expression predicts worse overall survival (hazard ratio [HR] = 1.48; 95% confidence interval [CI] = 1.119-1.966; P = .0061). Survival analysis showed 10-year survival of 53.1% for patients with high stathmin expression versus 67% for low expressers (log-rank, P < .003). Cox multivariate analysis showed high stathmin expression was independent of age, menopausal status, nodal status, nuclear grade, tumor size, and estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression (HR = 1.19; 95% CI = 1.03-1.37; P = .01). The ratio of MAP-tau to stathmin expression showed a positive correlation to disease-free survival (HR = 0.679; 95% CI = 0.517-0.891; P = .0053) with a 10-year survival of 65.4% for patients who had a high ratio of MAP-tau to stathmin versus 52.5% 10-year survival rate for those with a low ratio (log-rank, P = .0009). Cox multivariate analysis showed the ratio of MAP-tau to stathmin was an independent predictor of overall survival (HR = 0.609; 95% CI = 0.422-0.879; P = .008).
Low stathmin and high MAP-tau are associated with increased microtubule stability and better prognosis in breast cancer. Cancer 2012. © 2012 American Cancer Society.